---
schema_version: "secwatch.filing_event.v1"
accession: "0001159036-23-000056"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T19:06:24.502213+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Halozyme Q3 royalty revenue up 15% to $114.4M; raises 2023 EBITDA & EPS guidance

## Summary
- GAAP diluted EPS $0.61, non-GAAP $0.75; royalty revenue $114.4M (+15% YoY).
- Total revenue $216M (+3% YoY); operating income $88.3M vs $83.3M.
- Accelerates remaining $250M share repurchase into 2023 via ASR (immediate).
- Raises 2023 EBITDA guidance to $430-445M, non-GAAP EPS to $2.70-2.80.
- Partner milestones: positive CheckMate-67T, Phesgo Japan approval, Tecentriq SC US launch delay to 2024.

## SEC filing metadata
- accession: 0001159036-23-000056
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000115903623000056/0001159036-23-000056-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000115903623000056/halo-20231106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001159036-23-000056
- JSON: https://secwatch.observer/filing/0001159036-23-000056.json
- Plain text: https://secwatch.observer/filing/0001159036-23-000056.txt

## Key facts
- Earnings Releases
  HALOZYME THERAPEUTICS, INC. reported third quarter ended September 30, 2023 results: revenue $216.0 million, EPS $0.61. Guidance raised.
  - Period: third quarter ended September 30, 2023
  - Revenue: $216.0 million
  - EPS: $0.61
  - Guidance: raised
  - Result: reported results
  source text: endpoints in patients with relapsing forms of multiple sclerosis (“MS”) or primary progressive MS (“RMS” or “PPMS”). Third Quarter 2023 Financial Highlights: • Revenue was $216.0 million compared to $209.0 million in the third quarter of 2022. The 3% year-over-year increase was driven by growth in ENHANZE ® revenue streams with an increase in royalty revenue and
  evidence_url: https://www.sec.gov/Archives/edgar/data/1159036/000115903623000056/0001159036-23-000056-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.